Canopy Growth (WEED.TO) has expanded its international footprint with the legalization of cannabis in U.K, as reported in a recent article.
“Mark Ware, chief medical officer for Canopy Growth (which generated $80 million in sales last year), said a new U.K. subsidiary, Spectrum Biomedical, would begin importing and distributing cannabis to pharmacies at the request of physicians in the first half of 2019,” The Telegraph reports.
Spectrum Cannabis, a wholly owned subsidiary of Canopy Growth, aims to simplify cannabis for medical patients and healthcare practitioners. Operating in Australia, South America, Africa and across Europe, the company’s products line-up includes whole flower cannabis, oils and new innovations, such as Softgels.
In a landmark decision, the British government allowed the use of cannabis for medical use on Nov. 1, 2018. The announcement implies that doctors can now legally prescribe medical cannabis to their patients in the U.K.
In an official statement, Home Secretary Sajid Javid said: “Having been moved by heartbreaking cases involving sick children, it was important to me that we took swift action to help those who can benefit from medicinal cannabis.”
Source: 420 Intel
View Original Post